Hugel (145020) Q1 2026 earnings summary

Executive summary

• Net sales for Q1 2026 reached KRW 116.6 billion, up 29.9% year-over-year, with operating profit of KRW 47.6 billion and net income of KRW 40.6 billion, reflecting continued growth in core product lines.

• The company maintains a strong cash position of KRW 249.3 billion and low net debt, with robust liquidity and capital structure.

• Major product segments include botulinum toxin, HA fillers, cosmetics, and threads, with significant international sales.

• The company is expanding into dermal regeneration and ECM-based products, targeting high-growth medical aesthetics markets.

Financial highlights

• Gross profit for Q1 2026 was KRW 90.1 billion, up 30.5% year-over-year, with a gross margin of 77.2%.

• SG&A expenses increased 41.2% year-over-year to KRW 42.5 billion.

• Pre-tax income rose 36.6% year-over-year to KRW 56.1 billion.

• R&D expenses were KRW 3.1 billion in Q1 2026, 2.67% of sales.

• Cash and cash equivalents stood at KRW 249.3 billion as of March 31, 2026.

Outlook and guidance

• International sales momentum remains strong, especially in North & South America and Asia Pacific.

• The company is targeting continued global expansion, especially in the US, Europe, and Asia, leveraging recent regulatory approvals.

• New business lines in dermal regeneration and ECM products are expected to drive future growth.

• Ongoing investment in R&D and production capacity to support product pipeline and international sales.